Abstract:Objective To analyze the clinical effects of Xinmailong Injection in the treatment of sepsis complicated with heart failure. Methods From December 2016 to November 2018, 100 patients with sepsis and heart failure admitted to the First Central Hospital of Baoding City in Hebei Province were selected as subjects. According to the principle of random number table, patients were divided into control group and observation group, 50 cases in each group. Patients in control group received anti-infective and anti-heart failure treatments. Patients in observation group received Xinmailong Injection on this basis. Both groups were treated for 7 days. Lee′s heart failure score, cardiac function index [Left ventricular ejection fraction (LVEF), cardiac output (CO), shortening fraction of left ventricle (SFLV), and stroke volume (SV)] were used to evaluate the degree of heart failure and cardiac function. The differences between the above indicators and PCT and BNP levels were compared between two groups. Results After treatment, Lee′s heart failure score in both groups was lower than that before treatment, and observation group was lower than that in control group, the difference was statistically significant (P < 0.05). After treatment, LVEF, CO, SFLV and SV of two groups were higher than those before treatment, and observation group was higher than control group, the difference was statistically significant (P < 0.05). After treatment, the serum PCT and BNP levels of two groups were lower than those before treatment, and observation group was lower than control group, the difference was statistically significant (P < 0.05). Conclusion Xinmailong Injection can effectively reduce the score of Lee′s heart failure in patients with sepsis and heart failure, improve heart function, and reduce serum PCT and BNP levels.
杨晰晰 曹东▲ 刘倩 邓凯 梁青 田新 安洪明 李雷. 心脉隆注射液治疗脓毒血症合并心力衰竭的临床效果[J]. 中国医药导报, 2019, 16(23): 142-145.
YANG Xixi CAO Dong▲ LIU Qian DENG Kai LIANG Qing TIAN Xin AN Hongming LI Lei. Clinical effect of Xinmailong Injection in the treatment of sepsis combined with heart failure. 中国医药导报, 2019, 16(23): 142-145.